Healthcare / BiotechnologyNYSE
$4.96
+0.18 (+3.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-130.6M · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-66.9%
↓Gross Margin
85.2%
↑Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-289.0%
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $62.9M · net income $-204.6M · FCF $-181.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $62.9M | $62.9M | $7.9M | — | — | — | — |
| Net Income | $-204.6M | $-204.6M | $-567.9M | $-75.8M | $-104.2M | $-86.8M | $-41.7M |
| EBITDA | $-189.2M | $-189.2M | $-566.9M | $-75.6M | $-119.5M | $-93.1M | $-43.4M |
| EPS | — | — | -2.11 | -0.35 | -0.48 | -0.44 | — |
| Gross Margin | 85.2% | 85.2% | 10.1% | — | — | — | — |
| Operating Margin | -338.7% | -338.7% | -2128.2% | — | — | — | — |
| Net Margin | -325.3% | -325.3% | -7213.8% | — | — | — | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.19 | 0.19 | 0.02 | 0.01 | 0.01 | — | — |
| Current Ratio | 7.44 | 7.44 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-181.8M | $-181.8M | $-130.6M | $-68.1M | $-96.5M | — | — |
| Returns | |||||||
| ROE | -66.9% | -66.9% | -122.5% | -12.5% | -15.9% | -11.6% | -19.4% |
| Valuation | |||||||
| P/B | 5.62 | 5.62 | 1.67 | 0.54 | 0.66 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 699.0% | 699.0% | — | — | — | — | — |
| EPS Growth | — | — | -502.9% | 27.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+134.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.11 → n/d
Residual
+134.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.